AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2018
Oct 9, 2018
31289_dirs_2018-10-09_663748f9-ea00-4b1a-b958-235505a3fbfc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2018-10-08
Reporting Person: Davis Todd C (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-10-08 | Common Stock | S | 2500 | $253.9912 | Disposed | 42556 | Direct |
Footnotes
F1: The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on September 06, 2018, in accordance with Rule 10b5-1.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.48 to $256.77, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.